This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Cholangiocarcinoma

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Cholangiocarcinoma is an adenocarcinoma that may arise from anywhere in the biliary tree from small intra-hepatic bile ducts to the common bile duct.

Most occur at the porta hepatis. Distal tumours obstruct main ducts and present early; intrahepatic tumours present late and may be mistaken for hepatocellular carcinoma.

In the UK, there are approximately 20 new cases per 1,000,000 per year.

Cholangiocarcinoma is more common in males because of the predominant occurrence of primary sclerosing cholangitis (PSC) in men

The prognosis is poor:

  • 5-year survival of less than 5%
  • median survival for patients with intrahepatic cholangiocarcinoma is expected to be 18-30 months. A slightly shorter survival has been reported for patients with perihilar cholangiocarcinoma (12-24 months)
  • cure can only be expected from surgical resection of early stage tumour
    • after surgery, the 5-year recurrence rate is in the range of 60-90%. Since most patients initially present with advanced disease, they are not amenable to primary surgical resection; 75% of patients die within 1 year of diagnosis
  • death is usually due to hepato-cellular failure and infection.

Reference:

  • 1. Khan SA et al. Cholangiocarcinoma. Lancet 2005;366:1303-1314.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.